Royal Bank of Canada’s Ambrx Biopharma Inc AMAM Stock Holding History

Royal Bank of Canada’s Portfolio AMAM Stock Details AMAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-70,094	Closed	-$998K	–	7826
2023 Q4	$998K	Buy	70,094 +63,594	+978%	+$723K	﹤0.01%	3672
2023 Q3	$75K	Buy	+6,500	New	+$88.5K	﹤0.01%	5563
2022 Q4	–	Sell	-42,453	Closed	-$46K	–	7927
2022 Q3	$46K	Buy	+42,453	New	+$87.4K	﹤0.01%	5786

Royal Bank of Canada's AMAM Position: Q1 2024 in Review

Royal Bank of Canada sold out of Ambrx Biopharma Inc (AMAM) in Q1 2024, closing a stake of 70,094 shares — an estimated $998K sold.

Royal Bank of Canada first reported a position in AMAM in Q3 2022 and held it in 3 quarters. The position peaked at $998K in Q4 2023. 0 funds tracked by Wall St. Rank hold AMAM as of Q1 2024.

Royal Bank of Canada reported no remaining Ambrx Biopharma Inc position as of Q1 2024 after selling out during the quarter.
Royal Bank of Canada sold 70,094 Ambrx Biopharma Inc shares in Q1 2024, an estimated $998K.
Royal Bank of Canada first reported a position in Ambrx Biopharma Inc in Q3 2022 and held it in 3 quarters.
Royal Bank of Canada's Ambrx Biopharma Inc position peaked at $998K in Q4 2023.
0 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q1 2024.

Based on Royal Bank of Canada's 13F filing for Q1 2024, filed 15 May 2024.